Pharmacogenetic Association of Kcnj11 (E23k) Variant With Therapeutic Response to Sulphonylurea (Glibenclamide) in Iranian Patients

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Pharmacogenetic Association of Kcnj11 (E23k) Variant With Therapeutic Response to Sulphonylurea (Glibenclamide) in Iranian Patients Publisher

Rastegari A¹ ; Rabbani M¹ ; Sadeghi HM¹ ; Imani EF² ; Hasanzadeh A³ ; Moazen F¹

Show Affiliations

1. Department of Pharmaceutical Biotechnology, Isfahan University of Medical Sciences, Isfahan, Iran
2. Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Science, Isfahan, Iran
3. Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Science, Isfahan, Iran

Source: International Journal of Diabetes in Developing Countries Published:2015

Abstract

[No abstract available]

Style	Citing Format
MLA	Rastegari A, et al.. "Pharmacogenetic Association of Kcnj11 (E23k) Variant With Therapeutic Response to Sulphonylurea (Glibenclamide) in Iranian Patients." International Journal of Diabetes in Developing Countries, vol. 35, no. 4, 2015, pp. 630-631.
APA	Rastegari A, Rabbani M, Sadeghi HM, Imani EF, Hasanzadeh A, Moazen F (2015). Pharmacogenetic Association of Kcnj11 (E23k) Variant With Therapeutic Response to Sulphonylurea (Glibenclamide) in Iranian Patients. International Journal of Diabetes in Developing Countries, 35(4), 630-631.
Chicago	Rastegari A, Rabbani M, Sadeghi HM, Imani EF, Hasanzadeh A, Moazen F. "Pharmacogenetic Association of Kcnj11 (E23k) Variant With Therapeutic Response to Sulphonylurea (Glibenclamide) in Iranian Patients." International Journal of Diabetes in Developing Countries 35, no. 4 (2015): 630-631.
Harvard	Rastegari A et al. (2015) 'Pharmacogenetic Association of Kcnj11 (E23k) Variant With Therapeutic Response to Sulphonylurea (Glibenclamide) in Iranian Patients', International Journal of Diabetes in Developing Countries, 35(4), pp. 630-631.
Vancouver	Rastegari A, Rabbani M, Sadeghi HM, Imani EF, Hasanzadeh A, Moazen F. Pharmacogenetic Association of Kcnj11 (E23k) Variant With Therapeutic Response to Sulphonylurea (Glibenclamide) in Iranian Patients. International Journal of Diabetes in Developing Countries. 2015;35(4):630-631.
BibTex	@article{ author = {Rastegari A and Rabbani M and Sadeghi HM and Imani EF and Hasanzadeh A and Moazen F}, title = {Pharmacogenetic Association of Kcnj11 (E23k) Variant With Therapeutic Response to Sulphonylurea (Glibenclamide) in Iranian Patients}, journal = {International Journal of Diabetes in Developing Countries}, volume = {35}, number = {4}, pages = {630-631}, year = {2015} }
RIS	TY - JOUR AU - Rastegari A AU - Rabbani M AU - Sadeghi HM AU - Imani EF AU - Hasanzadeh A AU - Moazen F TI - Pharmacogenetic Association of Kcnj11 (E23k) Variant With Therapeutic Response to Sulphonylurea (Glibenclamide) in Iranian Patients JO - International Journal of Diabetes in Developing Countries VL - 35 IS - 4 SP - 630 EP - 631 PY - 2015 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract